AstraZeneca Aims to Double its Turnover Until 2030, up to 73.7 Billion Euros

The British laboratory AstraZeneca has set a goal of reaching sales of $80 billion by 2030 by betting on treatments against cancer, rare diseases and other conditions, as revealed this Tuesday, May 21st, at its Investor Day. In this way, the company aims to practically double the turnover recorded in 2023 , which amounted to $45.8 billion, by the end of the decade, through the commercialization of twenty drugs of relevance by then.

As explained by its CEO, Pascal Soriot, twelve of these drugs have the potential to generate more than 5 billion dollars a year , of which five would be for cancer. “AstraZeneca today announces a new era of growth,” said Soriot. “The breadth of our portfolio along with continued investment in innovation supports sustained growth well beyond the end of the decade,” he added.

In addition, the manager has also maintained that the company’s solid position in emerging markets will be vital to achieving its growth objectives. Thus, the company is the largest drug manufacturer by sales in China and has an important research and development center in Shanghai .

AstraZeneca is also betting on radiopharmaceuticals. In this sense, the laboratory agreed earlier this year to purchase Fusion Pharmaceuticals for $2.4 billion.

AstraZeneca has announced who will be its new financial director in Spain

AstraZeneca’s Investor Day has coincided with the announcement of changes in its management in Spain. The British pharmaceutical company today announced the appointment of Luis Miguel Carrasco as its new financial director. Carrasco, who has been within the company for more than a decade managing multidisciplinary and international teams, “assumes this new role with the aim of consolidating AstraZeneca’s financial position in the pharmaceutical sector and strengthening its presence in Spain,” reads the company’s statement. company.

Luis Miguel Carrasco has a degree in Economics and has a master’s degree in Multinational Management from the Autonomous University of Madrid (UAM) and another in Financial Management from Esade. In addition, he has complemented his training at institutions such as Cranfield School of Management and Wharton University. Currently, he has 23 years of experience in corporate finance .

In 2014, Carrasco joined AstraZeneca as head of finance business partner for Oncology&Medical and, after managing the creation of the Oncology unit in 2016, assumed the role of CFO for Central America and the Caribbean in 2020, overseeing more than 20 markets.

__

(Featured image by Marek Studzisnki via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us